Last reviewed · How we verify
Vγ2Vδ2 T lymphocyte-based immunotherapy
Vγ2Vδ2 T lymphocyte-based immunotherapy activates and expands a specialized subset of gamma-delta T cells to enhance anti-tumor immune responses.
Vγ2Vδ2 T lymphocyte-based immunotherapy activates and expands a specialized subset of gamma-delta T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (specific indications not fully characterized in public literature).
At a glance
| Generic name | Vγ2Vδ2 T lymphocyte-based immunotherapy |
|---|---|
| Also known as | Drug combination (zoledronic acid/interleukin 2) |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | Cell-based immunotherapy |
| Target | Vγ2Vδ2 T cell receptor; phosphoantigens and stress-induced ligands |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Vγ2Vδ2 T cells are innate-like lymphocytes that recognize phosphoantigens and stress-induced ligands on tumor and infected cells. This therapy involves ex vivo expansion and/or in vivo activation of these cells to promote cytotoxic killing of malignant cells and enhance overall anti-tumor immunity. The approach leverages the unique ability of gamma-delta T cells to bridge innate and adaptive immunity without requiring MHC presentation.
Approved indications
- Advanced or metastatic solid tumors (specific indications not fully characterized in public literature)
Common side effects
- Cytokine release syndrome
- Fever
- Fatigue
- Infusion-related reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: